Purpose: Azacitidine (AZA) is a novel therapeutic option in older patients with acute myeloid leukemia (AML) but its rational utilization is compromised by the fact that neither the determinants of clinical response nor its mechanism of action are defined.
Statement of translational relevance:
The clinical benefit of azacitidine (AZA) monotherapy in acute myeloid leukemia (AML) is blunted by low response rates and the inevitability of disease progression.
Combination therapy with histone deacetylase (HDAC) inhibitors has been proposed to improve outcome but has not been prospectively studied in AML. The demonstration in this randomized study that co-administration of AZA with the HDAC inhibitor vorinostat does not improve outcome in newly diagnosed or relapsed AML confirms the importance of identifying new therapeutic partners for AZA. In this context the observation that mutations in the cell cycle checkpoint activator CDKN2A correlate with adverse clinical outcome represents the first clinical validation of in vitro data implicating induction of cell cycle arrest as a mechanism of AZA's clinical activity informing the design of novel drug combinations. Furthermore, persistence of stem/progenitor populations throughout therapy identifies their role as a biomarker of response to AZA based regimens.
Introduction
The DNA methyltransferase (DNMT) inhibitors azacitidine (AZA) and decitabine (DEC) represent important advances in the management of patients with acute myeloid leukemia (AML) and high-risk myelodysplasia (MDS) ineligible for intensive chemotherapy (1) . Recent randomized trials have demonstrated that AZA improves outcome in older adults with AML and high risk MDS (2, 3) . More recently AZA has been to shown to possess significant clinical activity in relapsed and refractory AML (4) (5) (6) . However, the clinical utility of AZA in both newly diagnosed and advanced disease is limited by relatively low rates of complete remission (CR) and the fact all patients relapse despite continuing therapy. There is consequently an urgent need to identify novel therapies with the potential to improve the outcome after AZA monotherapy. Co-administration of AZA with histone deacetylase (HDAC) inhibitors augments killing of leukemic cell lines in vitro (7) and single-arm trials have described increased clinical activity of AZA in combination with a number of HDAC inhibitors including sodium valproate and vorinostat (VOR) (4, 8, 9) . Although recent randomized trials have reported no benefit of co-administration combined AZA and HDAC inhibitor therapy in high-risk MDS there have been no randomized trials in AML (10) (11) (12) .
The development of pharmacological strategies to improve the outcome of AZA based therapy in AML has been hampered by our limited understanding of its mechanism of action. Whilst in vitro and animal studies demonstrate that induction of cell cycle arrest and up-regulation of cell cycle genes correlates with AZA's antileukemic activity the mechanism by which it exerts a clinical anti-tumor effect remains a matter of conjecture (7) . Furthermore, although disease progression appears inevitable in patients treated with AZA little is understood of the mechanism of disease resistance (13) . Recent immunophenotypic characterization of the stem/progenitor cell compartments containing leukemic stem cells (LSCs) in AML have demonstrated their persistence in a proportion of patients consistent with the hypothesis that this cellular population represents a reservoir of resistant disease although this proposition has not been prospectively examined in AZA treated patients (4, 14) .
We therefore examined whether co-administration of the HDAC inhibitor VOR increases response rates and OS in patients with AML and high risk MDS and correlated these clinical endpoints with both diagnostic genotypes and serial stem/progenitor quantitation. 
Subjects and Methods

Treatment regimens:
Patients were randomized on a 1:1 basis using a minimization algorithm with three variables: disease category (AML vs MDS), stage of disease (newly diagnosed vs relapsed / refractory) and age (<70 vs 70+). Patients in the control arm received AZA (75mg/m 2 ) by subcutaneous (SC) injection on a five-twotwo schedule, commencing on day one of 28-day cycles for up to six cycles. In the combination arm patients received the same schedule of AZA in conjunction with additional VOR (300mg bd) orally (po) for seven consecutive days commencing on day three of each cycle. All study participants achieving a CR, CR with incomplete blood count recovery (CRi), marrow CR (mCR) or partial response (PR) within the first six cycles of treatment, were permitted to continue study treatment until loss of response. Non-responding patients discontinued trial therapy. Bone marrow samples for morphology and immunophenotypic assessment were collected after cycles three and six and three months thereafter. Compliance to treatment was defined as the number of patients who received treatment as planned according to the trial protocol.
Efficacy endpoints: Two primary endpoints were defined: overall response rate (ORR) and overall survival (OS). ORR was defined as acquisition of CR, CRi, mCR or PR within six cycles of treatment utilizing modified Cheson or IWG criteria (16, 17) . For each patient the response after the third and sixth cycle of trial treatment was reviewed and the better of the two was considered the 'best response' and used 
Bioinformatic analysis
Sequencing quality was assessed using FASTQC (Samtools) and aligned using a Antibodies used in the lineage (Lin) depletion cocktail were: anti-CD2, anti-CD3, anti-CD4, anti-CD8a, anti-CD10, anti-CD19, anti-CD20 and anti-CD235a. Antibodies used to analyze different subpopulations were: anti-CD34, anti-CD38, anti-CD90, anti-CD45RA, anti-CD123, anti-CD117, and 7AAD were used as a live/dead stain. Supplemental Table 4 . We did not deplete CD11b, CD14, CD7, CD56 expressing cells as these markers may be expressed by CD34+ and CD34-CD117+ LSC populations. We assessed LSC populations pre-treatment, during treatment and in a subset of patients, at relapse. Table 5 ). An example of the gating strategy is demonstrated in Supplemental Figure 1 .
Details of each antibody/streptavidin are listed in
Statistical analysis:
The sample size was calculated on conventional phase III criteria but with a relaxed alpha and was originally powered to recruit 160 patients (ORR: P 0 = 15%, detectable difference=15%, 2-sided α and β =0. 15 There was no difference in dose intensity across treatment arms with a median intensity of 100% of the dose delivered in the first six cycles of treatment. 106 patients in the AZA arm experienced one or more toxicity compared to 110 patients in the combination arm and there was no difference between treatment arms (P=0.87). Adverse events (Grade 3 and 4) experienced by 5% or more of patients are listed in Supplemental Table 6 .
Response and survival:
There was no difference in either ORR (41% versus 42%) (OR=1.05 (95% CI: 0.64, 1.72), P=0.84) or CR/CRi/mCR rate (22% and 26%) (OR=0.82 (95% CI: 0.46, 1.45), P=0.49) between the control and combination therapy arms. Time to first response and duration of response at one year was similar in the AZA and combination arm (6.2 vs 5.7 months and 67% vs 58% respectively) (Supplemental Figure 2) . In pre-determined subgroup analysis patients with relapsed/refractory disease demonstrated an increased CR in the AZA/VOR arm (P=0.02), although this did not translate to an improvement in OS.
No difference was observed in OS between patients treated with AZA monotherapy (median OS: 9.6 months (95% CI: 7.9, 12.7)) and patients in the AZA/VOR arm (median OS: 11.0 months (95% CI: 8.5, 12.0)) (HR=1.15 (95% CI: 0.87, 1.51), The impact of diagnostic mutational status on clinical response and OS was then studied using the results of NGS performed on 250 patients at trial entry ( Figure 3A) .
The mean mutation number per patient was 3.4 ( Figure 3B ). Mutations in RUNX1 were most frequent (73 patients, 29%). Mutations in DNMT3A (59 patients 23%), IDH2 (57 patients, 23%) and TET2 (56 patients, 22%) were also common ( Figure   3A ). The observed mutational frequency was broadly consistent with that previously reported in older, but not younger, AML and MDS patients(19-21) ( Figure 3C ). In univariate analysis there was a lower complete response (CR, CRi, mCR) rate in patients with an IDH2 mutation (P=0.029) and STAG2 mutation (P=0.002) but an increased CR rate in patients with an NPM1 mutation (P=0.038) ( Table 2) . When considered in a multivariable analysis adjusted for all clinical variables, the presence of STAG2 and IDH2 mutations was not shown to have a significant association with acquisition of CR (Table 2 ). However, NPM1 mutation remained of prognostic significance (P=0.012).
Mutations in CDKN2A (P=0.0001), IDH1 (P=0.004), TP53 (P=0.003), NPM1 (P=0.037) and FLT3-ITD (P=0.04) were associated with reduced OS in univariate analysis. In multivariate analysis adjusted for all clinical variables, mutations in CDKN2A, IDH1 and TP53 were associated with decreased OS ( Table 2) . No mutations were associated with improved OS. Mutations in ASXL1 (P=0.035) and ETV6 (P=0.033) were associated with a reduced duration of response. No mutations were associated with improved duration of response.
Amongst other frequently co-occurring mutations, we observed significant cooccurrence of NPM1 mutations with DNMT3A, FLT3-ITD, FLT3-other and IDH1 as well as DNMT3A with FLT3-other, IDH1 and IDH2 (P<0.05 for all comparisons).
Patients with mutations in both DNMT3A and IDH1 had reduced OS (median OS 9.8 months, 95% CI: 1.5-11.6 months) compared to patients without both mutations (median OS 10.7, 95%CI: 8.9-12). Patients with both NPM1 and IDH1 mutations had reduced OS (median OS 3.8 months, 95%CI: 1.6-NE) compared to patients without both mutations (median OS 10.7, 95%CI: 9.0-11.8). No significantly co-occurring mutations were found to be predictors of acquisition of CR ( Figure 3D ).
Impact of AZA based therapy on the LSC population:
An expanded CD34 + progenitor population was observed in 42/45 studied patients at diagnosis, while a CD34expanded precursor population was observed in 3/45 ( Figure 4A ). The majority of expanded populations were lymphoid-primed multi-potential progenitors (LMPP: Lin-CD34+CD38-CD90-CD45RA+), which have been previously characterized as an LSC population with functional leukemia-propagating activity in serial xeno-transplant assays (14) , and as a novel biomarker of AML disease response and relapse (4) . Quantitatively, the immunophenotypic LMPP population is usually very small in normal bone marrow (<2 in 10 5 cells -Vyas et al data under review). Therefore, expansion of the LMPP population can be a sensitive measure of residual disease at CR in AML patients. For these reasons, we focused on quantitation LMPP by immunophenotyping to measure the impact of therapy on putative LSC populations at best response and relapse.
In seven patients with resistant disease, there was no reduction in LMPP numbers measured as a fold change ( Figure 4B ). Of interest, there was no significant reduction of LMPP numbers in eight patients achieving a PR, where the average bone marrow blast percentage was reduced by 50%. In contrast, in 22 CR/Cri/mCR patients there was a significant reduction in LMPP numbers with AZA-based therapy.
However, even here LMPP numbers failed to normalize in 16/22 ( Figure 4B ). In seven patients with expanded LMPP numbers, who achieved a CR, sequential monitoring demonstrated expansion progenitor populations prior to disease relapse ( Figure 4C ).
Discussion
Co-administration of the HDAC inhibitor VOR did not improve response or survival in patients with AML or MDS treated with AZA. This observation is consistent with previous randomized studies in high risk MDS but is the first demonstration that HDAC inhibitors have no impact on clinical outcomes in patients with newly diagnosed or relapsed AML treated with AZA (10) (11) (12) . Why might our study have failed to replicate earlier single arm studies of strikingly increased clinical activity of combined AZA and HDAC inhibitor treatment (8, 9, 22) The search for novel drug partners with the potential to improve the clinical activity of AZA has been hampered by the fact that its mechanism of clinical activity remains unknown. Cell line and animal data have identified up-regulation of epigenetically silenced genes and consequent restoration of cell cycle checkpoints as an important potential mechanism of action and indeed previous in vitro studies have correlated the ant-tumor activity of both AZA and DEC with their ability to effect changes in cell cycle gene expression and induce G2 phase arrest (7, 23, 24) . Consequently, the observation that heterozygous predicted loss of function mutations in CDKN2A, a cell cycle checkpoint activator, are correlated with decreased survival in AZA treated patients is supportive of the hypothesis that induction of cell cycle arrest is a potentially important mechanism of action of this agent. In our study the CDKN2A mutations were nonsense in two patients and in the other seven were either nonsynonymous SNVs that had previously been reported (six patients) or within two codons of a previously reported mutation (one patient). CDKN2A encodes P14, P16 and ARF. P14 and P16 inhibit the cyclin dependent kinase CDK4 which regulates the G1 cell cycle checkpoint. ARF sequesters the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. Thus, if loss of CDKN2A abrogates the clinical activity of AZA it raises the possibility that AZA induces G1 cell cycle arrest and requires at least some p53 function for its anti-leukemic activity. We acknowledge that the findings of this study are based on a small sample size and that it is important to replicate this clinical association of CDKN2A mutations with poor clinical response to AZA in larger studies. If confirmed, our data highlight further study of P14, P16 and ARF function as a potentially fruitful line of investigation in understanding and potentially improving the outcomes of AZA based therapy.
The identification of both clinical and molecular predictors of outcome with AZA therapy is important if this agent is to be optimally deployed. Improved survival noted was observed in patients with newly diagnosed disease, a low presentation white count and ECOG score. Importantly, and in contrast to patients treated with myelosupressive chemotherapy, we observed no impact on survival of an adverse risk karyotype after AZA based therapy (25) . Our data also demonstrate that NGS improves risk stratification since mutations in CDKN2A, IDH1 and TP53 were independently associated with decreased survival in AZA-treated patients. We did not identify any impact of mutations in TET2 or DNMT3A on outcome, in contrast to previous smaller retrospective studies (26) (27) (28) (29) . Although TP53 mutations have previously been shown to be associated with decreased survival in patients treated with intensive chemotherapy (30) it has recently been reported that the presence of a TP53 mutation was associated with a higher response rate in patients treated with DEC (21) . In contrast our data demonstrating no impact of TP53 on response rate to AZA but decreased OS in mutated patients implies that these two DNMT inhibitors may have distinct mechanisms of action (16, 20, 33) . The remaining authors have nothing to disclose. 17 
